Serum adiponectin is positively associated with lung function in young adults, independent of obesity: The CARDIA study

Table 4 Association between year 15 serum adiponectin concentrations and change in lung function over 10 years (year 20-year 10); CARDIA "calendar years".

*Year 15 adiponectin quartiles (Q)*	10 YEAR DECLINE IN LUNG FUNCTION PARAMETERS (95% CI)
	MODEL 1 (n = 2,056)	MODEL 2 (n = 2,056)
	FVC (ml) ± SE
Q1	-383 ± 14	-374 ± 14
Q2	-385 ± 14	-383 ± 14
Q3	-389 ± 13	-392 ± 13
Q4	-383 ± 14	-390 ± 14
Q1 minusQ4	0 (-42, 42)	16 (-27, 59)
Slope of ln(adiponectin)*	7 (-27, 41)	22 (-14, 57)
	p for trend = 0.69	p for trend = 0.22
	FEV ₁ (ml) ± SE
Q1	-348 ± 11	-343 ± 11
Q2	-352 ± 12	-351 ± 12
Q3	-367 ± 11	-369 ± 11
Q4	-360 ± 12	-364 ± 12
Q1 minus Q4	12 (-22, 46)	21 (-14, 56)
Slope of ln(adiponectin)*	19 (-9, 47)	28 (-1, 56)
	p for trend = 0.17	p for trend = 0.05
	FEV1/FVC (%) ± SE
Q1	-1.08 ± 0.17	-1.13 ± 0.18
Q2	-1.13 ± 0.18	-1.13 ± 0.18
Q3	-1.43 ± 0.17	-1.40 ± 0.17
Q4	-1.44 ± 0.18	-1.40 ± 0.18
Q1 minus Q4	0.36 (-0.17, 0.89)	0.27 (-0.27, 0.82)
Slope of ln(adiponectin)*	0.34 (-0.09, 0.77)	0.26 (-0.18, 0.71)
	p for trend = 0.11	p for trend = 0.24

Note 1: Model 1 was adjusted for race, sex, center, age, age², amount of self-reported physical activity, body mass index (BMI) and smoking status (never, former, current) all at year 15 and height, height²at year 0. Model 2 was adjusted for all covariates in model 1 and for ln(insulin resistance in HOMA units) and ln(CRP) at year 15 examination.
Note 2: Quartile cutpoints for serum adiponectin concentrations are ≤6.99, 7.00-9.59, 9.60-14.39, and ≥ 14.40 mg/l. Mean ± standard deviation of ln(adiponectin) = 2.21 ± 0.62 mg/l
* Unit of slope was selected to match the adiponectin difference across Q1 to Q4. It was ml/(median level of adiponectin in quartile 1 (4.8 mg/l) - median level of adiponectin in quartile 4 (18.0 mg/l)).

ISSN: 1465-993X